预约演示

更新于：2025-05-07

Chlormezanone

氯美扎酮

更新于：2025-05-07

概要

基本信息

药物类型

小分子化药

别名

(±)-chlormezanone、2-(p-chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide、2-(p-chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide

+ [4]

靶点

TSPO

作用方式

刺激剂

作用机制

TSPO刺激剂(TSPO蛋白刺激剂)

治疗领域

神经系统疾病皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

焦虑症肌肉痉挛

原研机构

Sanofi

在研机构-

非在研机构

Sanofi-Aventis U.S. LLC

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1960-05-20),

焦虑症肌肉痉挛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C11H12ClNO3S

InChIKeyWEQAYVWKMWHEJO-UHFFFAOYSA-N

CAS号80-77-3

关联

项与氯美扎酮相关的临床试验

NCT02582736

/ CompletedN/AIIT

Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data

The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency.
The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.

开始日期2012-04-01

申办/合作机构

Canadian Institutes of Health Research

100 项与氯美扎酮相关的临床结果

登录后查看更多信息

100 项与氯美扎酮相关的转化医学

登录后查看更多信息

100 项与氯美扎酮相关的专利（医药）

登录后查看更多信息

416

项与氯美扎酮相关的文献（医药）

2025-02-01·Chemical Engineering Journal

Dual Channel passivation enhancing stable perovskite Light-Emitting diodes

作者: Wang, Zhao-Kui ; Li, Nan ; Wang, Bin ; Chen, Xin ; Xia, Yu ; Huang, Lei ; Chen, Chun-Hao ; Li, Yu-Han ; Wang, Shao-Qi ; Chen, Jing ; Yang, Wei

Perovskite light-emitting diodes (PeLEDs) still faces the challenges such as poor film morphol. and inefficient energy transfer from the small-n phase to the large-n phase leading to rapid efficiency degradation and instability in high temperatureTo address these issues, herein, chlormezanone was employed to modify the perovskite film.Combined beneficial points were obtained including improved film morphol., reduced luminescence quenching, enhanced phase distribution and energy transfer by suppressing small-n phases, and defect mitigation at grain boundaries/interfaces via passivation groups (C = O, S = O).Consequently, the fabricated sky-blue PeLEDs delivered an external quantum efficiency of 10.14 % and an operating lifetime (T₅₀) of 23.1 min, which was twice as long as the control device.This developed strategy significantly enhanced the stability while maintain excellent efficiency, providing a solid foundation for future investigation.

2024-09-20·ACS Catalysis

Ni-Catalyzed Deoxygenative Cross-Coupling of Alcohols with Aryl Chlorides via an Organic Photoredox Process

作者: Kang, Tengfei ; Xue, Dong ; Dong, Jianyang ; Liao, Huijuan ; Yan, Yonggang ; Li, Gang ; Xiong, Weikang ; Li, Fei

Cross-electrophile coupling from naturally abundant materials is of significant value in organic synthesis.Herein, we established a highly efficient deoxygenative cross-coupling reaction using alcs. and industrial preferred aryl chlorides as coupling partners by the merging of photoredox and nickel catalysis with diaryl ketone as a photocatalyst.This methodol. features a broad substrate scope and high functional group tolerance, with straightforward application of scale-up synthesis and late-stage modification of structurally complex natural products and pharmaceuticals, including C-4 alkylated pyridines.This protocol most likely proceeds via a HAT and β-scission process to form alkyl radicals from benzoxazolium salt-alc. adducts.

2024-08-07·Journal of the American Chemical Society

Late-Stage C(sp²)–C(sp³) Diversification via Nickel Oxidative Addition Complexes

Article

作者: Tan, Eric ; Castellanos-Blanco, Nahury ; Diéguez-Vázquez, Alejandro ; Santiago, Tomás G ; Chaves-Arquero, Belén ; Alonso, Jose Manuel ; Linares, María Lourdes ; Odena, Carlota ; Cañellas, Santiago ; McGuire, Ryan T ; Alcázar, Jesús ; Buijnsters, Peter ; Martin, Ruben

Herein, we describe nickel oxidative addition complexes (Ni-OACs) of drug-like molecules as a platform to rapidly generate lead candidates with enhanced C(sp³) fraction. The potential of Ni-OACs to access new chemical space has been assessed not only in C(sp²)-C(sp³) couplings but also in additional bond formations without recourse to specialized ligands and with improved generality when compared to Ni-catalyzed reactions. The development of an automated diversification process further illustrates the robustness of Ni-OACs, thus offering a new gateway to expedite the design-make-test-analyze (DMTA) cycle in drug discovery.

100 项与氯美扎酮相关的药物交易

登录后查看更多信息